Scott Matson, M.D.

Professional Background

Dr. Matson studied medicine (MD 2013) at the University of Kansas School of Medicine. Following graduation he completed internship and residency in internal medicine at the University of Colorado in Denver. He was selected in 2017 as chief medical resident at the University of Colorado. Following chief residency he completed a combined pulmonary and critical care fellowship at the University of Colorado and National Jewish Hospital. During his fellowship, Dr. Matson pursued advanced training in interstitial lung disease at the University of Colorado Center for Lungs and Breathing as well as National Jewish Hospital. At the University of Kansas, Dr. Matson sees patients in the Interstitial Lung Disease and Rare Lung Disease clinic as well as attends in the medical intensive care unit. He is a clinician scientist with a translational research focus of autoimmune lung disease.

• BM, Saxophone Performance , University of Kansas, Lawrence , KS
• MD, MD, University of Kansas School of Medicine , Kansas City, KS
• Internship, Internal Medicine, University of Colorado, School of Medicine GME, Denver, CO
• Residency, Internal Medicine , University of Colorado, School of Medicine, GME, Denver, CO
• Other, Internal Medicine , University of Colorado, School of Medicine, GME, Denver, CO
• Clinical Fellowship, Pulmonary and Critical Care, University of Colorado, School of Medicine, GME, Denver, CO

• Critical Care Medicine , American Board of Internal Medicine
• Doctor Of Medicine, Kansas Board of Healing Arts
• Doctor of Medicine, Missouri Division of Professional Registration
• Internal Medicine, American Board of Internal Medicine
• Pulmonary Medicine , American Board of Internal Medicine

---

Research

Overview

Dr. Matson studies autoimmune related interstitial lung diseases such as rheumatoid arthritis related ILD. His work is focused on identifying risk factors and biomarkers for the development of ILD in autoimmune diseases as well as the role of the lung and airway in autoantibody development. Additionally, Dr. Matson's research focuses on clinical research in ILD including evaluating important outcomes in treatment of these conditions.

• Precision medicine description of novel asthma endotype , NIH, PI

• Matson, S, Lee, J, Eickelberg, O. 2021. Two sides of the same coin? A review of the similarities and differences between idiopathic pulmonary fibrosis and rheumatoid arthritis-associated interstitial lung disease.. The European respiratory journal, 57 (5)
• Matson, S., M, Demoruelle, M., K, Castro, M. 2021. A Focused Review: Airways Disease in Rheumatoid Arthritis.. Annals of the American Thoracic Society
• Matson, S., M, Deane, K., D, Peljto, A., L, Bang, T., J, Sachs, P., B, Walts, A., D, Collora, C, Ye, S, Demoruelle, M., K, Humphries, S., M, Schwartz, D., A, Lee, J., S. 2021. Prospective Identification of Subclinical Interstitial Lung Disease in Rheumatoid Arthritis Cohort is Associated with the MUC5B Promoter Variant.. American journal of respiratory and critical care medicine
• Matson, S., M, Lee, S., J, Peterson, R., A, Achtar-Zadeh, N., A, Boin, F, Wolters, P., J, Lee, J., S. 2021. The prognostic role of matrix metalloproteinase-7 in scleroderma-associated interstitial lung disease.. The European respiratory journal, 58 (6)
• Matson, S., M, Griffith, M, Lee, J., S. 2021. FocuSSced on the Target in Systemic Sclerosis-Interstitial Lung Disease: Another Arrow in the Quiver?. American journal of respiratory and critical care medicine
• Graney, B., A, He, C, Marll, M, Matson, S, Bianchi, P, Cosgrove, G., P, Lee, J., S. 2021. Essential Components of an Interstitial Lung Disease Clinic: Results From a Delphi Survey and Patient Focus Group Analysis.. Chest, 159 (4), 1517-1530
• Solomon, J., J, Matson, S, Kelmenson, L., B, Chung, J., H, Hobbs, S., B, Rosas, I., O, Dellaripa, P., F, Doyle, T., J, Poli, S, Esposito, A., J, Visser, A, Marin, A., I, Amigues, I, Fernández Pérez, E., R, Brown, K., K, Mahler, M, Heinz, D, Cool, C, Deane, K., D, Swigris, J., J, Demoruelle, M., K. 2020. IgA Antibodies Directed Against Citrullinated Protein Antigens Are Elevated in Patients With Idiopathic Pulmonary Fibrosis.. Chest, 157 (6), 1513-1521